EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial

Marianna Jasenecova iD, Carl Coyle, Alina Mihalovits iD, Sarah Ryan, Elizabeth Pook, Esperanza Perucha, Gabrielle Harker, Melody Chin, Sam Norton iD, Andrew P Cope

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.70082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Marianna Jasenecova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Rheumatic Diseases, King's College London, London, United Kingdom. Hauptthemen laut MEDLINE: Abatacept, Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our study objective was to identify serum protein signatures associated with progression to rheumatoid arthritis (RA) and response to abatacept in at‐risk individuals.

Methods

A total of 440 serum samples from 118 APIPPRA (Arthritis Prevention In the Preclinical Phase of RA with Abatacept) study participants were selected from baseline to RA onset for 46 progressors of RA or to study end for 72 participants who did not develop RA. Samples were analyzed using the SomaScan 7k assay platform. Differential expression analysis was assessed by progression to RA (three pre‐RA time intervals to RA, progressors of RA vs nonprogressors, baseline to RA), and by treatment allocation (abatacept vs placebo). Risk and response signatures were identified in the full 7k panel and two prespecified subpanels defined as Inflammatory Mediators and Adaptive Immune Cell panel.

Results

We observed significant changes in 80 proteins (68 down‐regulated and 12 up‐regulated) occurring between RA onset and 6 to 24 months before developing disease. Progression to RA was associated with increased levels of acute‐phase reactants SAA1 and SAA2 and reductions in CTLA4, when compared to nonprogressors at the end of treatment. Two up‐regulated proteins (CTLA4 and CD86) and seven down‐regulated proteins (CXCL13, FCRL4, FCER2, CCL21, LTA|LTB, FDCSP, and IL22RA2) were observed in participants receiving abatacept compared to placebo regardless of RA outcome.

Conclusion

Protein signatures dominated by acute‐phase proteins define progression to RA, whereas changes associated with abatacept therapy highlight potential mechanisms of treatment response. Such signatures provide a better understanding of the immune landscape of the at‐risk phase, opening up the possibility of new treatment modalities for RA prevention. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptAntirheumatic AgentsArthritis, RheumatoidAdultAgedFemaleHumansMaleMiddle AgedDisease ProgressionProteomicsSerum Amyloid A ProteinRandomized Controlled Trials as TopicMulticenter Studies as TopicClinical Trials, Phase II as Topic

Substanzen

AbataceptAntirheumatic AgentsSerum Amyloid A Protein

Autor:innen und Institutionen

  • Centre for Rheumatic Diseases, King's College London, London, United Kingdom.

ORCID-Profile: Marianna Jasenecova, Alina Mihalovits, Sam Norton

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Jasenecova, M., Coyle, C., Mihalovits, A., Ryan, S., Pook, E., Perucha, E., Harker, G., Chin, M., Norton, S., & Cope, A. P. (2026). Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.70082

Vancouver

Jasenecova M, Coyle C, Mihalovits A, Ryan S, Pook E, Perucha E, et al. Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial. Arthritis & Rheumatology. 2026. doi:10.1002/art.70082

BibTeX
@article{Jasenecova2026,
  author = {Jasenecova, Marianna and Coyle, Carl and Mihalovits, Alina and Ryan, Sarah and Pook, Elizabeth and Perucha, Esperanza and Harker, Gabrielle and Chin, Melody and Norton, Sam and Cope, Andrew P},
  title = {Serum Proteomic Signatures of Rheumatoid Arthritis Risk and Response: Analysis of a Rheumatoid Arthritis Interception Trial},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.70082}
}
Kostenlos starten →